Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia

05:33 PM EDT, 09/02/2026 (MT Newswires) -- Cogent Biosciences (COGT) said Wednesday in a filing that it entered into a commercial supply agreement with Hovione FarmaCiencia on Tuesday to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. Under the agreement, Cogent will purchase the products pursuant to rolling forecasts and source specified minimum percentages of its requirements for each product from Hovione, with those percentages decreasing over the term of the agreement, according to the filing. The agreement has an initial five-year term, followed by successive automatic two-year renewals, the filing added.